U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241390) titled 'A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)' on Nov. 17.
Brief Summary: The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Atherosclerosis Cardiovascular Disease
Chronic Kidney Disease
Intervention:
DRUG: Orforglipron
Administered oral...